Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg

Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)

Zydus receives final approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg

Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhoea

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90

Bluecrux supports Sanofi in harnessing AI to transform supply chains

Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.

Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome

Around 7% of the Indian population suffers from IBS

100 bedded Yoga & Naturopathy Hospital to come up in Dibrugarh

Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy

Bayer and Recursion focus research collaboration on Oncology

Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients

Biocon Biologics announces leadership appointments

Yaral Pharma launches diclofenac epolamine topical system 1.3%

Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment

Sonowal inaugurates Regional Research Institute of Unani Medicine in Silchar

The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine